Diagnostic value of heart-to-mediastinum ratio in
Amyloid heart disease
SPECT
diagnostic and prognostic application
Journal
Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
ISSN: 1532-6551
Titre abrégé: J Nucl Cardiol
Pays: United States
ID NLM: 9423534
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
16
06
2022
accepted:
26
11
2022
medline:
21
1
2024
pubmed:
21
1
2024
entrez:
20
1
2024
Statut:
ppublish
Résumé
In transthyretin cardiac amyloidosis (ATTR-CA), We retrospectively included 164 patients who underwent After the exclusion of patients who did not undergo endomyocardial biopsy, 30 patients (15 each with ATTR-CA and without ATTR-CA) were included. The receiver operating characteristic curve used to distinguish ATTR-CA from non-ATTR-CA patients revealed an area under the curve of 0.986 and 0.943, respectively. A H/M ratio of > 1.41 identified ATTR-CA patients with a sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of 100, 93.3, 93.3, and 100%, respectively. Conversely, an H/CL ratio of > 1.3 identified ATTR-CA patients with 100% sensitivity, 40.0% specificity, 62.5% PPV, and 100% NPV. The H/M ratio obtained at 3 hours post-injection has the potential to be a novel indicator for ATTR-CA.
Sections du résumé
BACKGROUND
BACKGROUND
In transthyretin cardiac amyloidosis (ATTR-CA),
METHODS
METHODS
We retrospectively included 164 patients who underwent
RESULTS
RESULTS
After the exclusion of patients who did not undergo endomyocardial biopsy, 30 patients (15 each with ATTR-CA and without ATTR-CA) were included. The receiver operating characteristic curve used to distinguish ATTR-CA from non-ATTR-CA patients revealed an area under the curve of 0.986 and 0.943, respectively. A H/M ratio of > 1.41 identified ATTR-CA patients with a sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of 100, 93.3, 93.3, and 100%, respectively. Conversely, an H/CL ratio of > 1.3 identified ATTR-CA patients with 100% sensitivity, 40.0% specificity, 62.5% PPV, and 100% NPV.
CONCLUSION
CONCLUSIONS
The H/M ratio obtained at 3 hours post-injection has the potential to be a novel indicator for ATTR-CA.
Identifiants
pubmed: 38245262
pii: S1071-3581(24)00032-1
doi: 10.1007/s12350-022-03180-5
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1374-1381Informations de copyright
Copyright © 2023 American Society of Nuclear Cardiology. Published by ELSEVIER INC. All rights reserved.